

Table S1. Prognostic factors for PFS of patients treated with Glofitmab.

Variables	PFS		
	HR	95% CI	<i>p</i> value
Sex	0.150	0.027-0.826	0.029
≥60 yr	5.528	0.648-47.137	0.118
Refractory to CAR-T cell therapy	0.946	0.183-4.893	0.947
Non-Hodgkin's lymphoma subtype			
DLBCL NOS	1.996	0.219-18.206	0.540
Transformed lymphoma	0.683	0.071-5.684	0.684
PMBL	0.041	/	0.739
Refractory to last previous therapy	1.510	1.04-2.192	0.030
Refractory to ASCT	0.307	0.034-2.790	0.294
Cell of origin: Non-GCB	1.256	0.145-10.916	0.836
Previous lines of therapy	0.994	0.603-1.638	0.982
Bulky disease > 6cm	0.689	0.133-3.559	0.657
LDH elevated	0.505	0.111-2.300	0.377
Extranodal involvement	2.280	0.978-5.318	0.056
CD3 ⁺ Count	0.999	0.997-1.000	0.136
CD3 ⁺ CD4 ⁺ Count	0.994	0.989-1.000	0.046
CD3 ⁺ CD8 ⁺ Count	0.999	0.996-1.001	0.227
%CD3 ⁺	1.010	0.953-1.069	0.704
%CD3 ⁺ CD4 ⁺	1.031	0.994-1.125	0.501
%CD3 ⁺ CD8 ⁺	0.998	0.947-1.051	0.927
CD4/CD8 ratio	2.009	0.313-12.891	0.462
%CD3 ⁻ CD16 ⁺ CD56 ⁺	1.002	0.949-1.058	0.941
%CD19 ⁺	0.947	0.840-1.068	0.376
%CD4 ⁺ CD25 ⁺	1.466	0.662-3.249	0.346
%CD8 ⁺ CD28 ⁻	1.010	0.958-1.066	0.693
%CD8 ⁺ CD28 ⁺	0.876	0.708-1.083	0.221

CAR-T, Chimeric antigen receptor-T; DLBCL, Diffuse large B cell lymphoma; PMBL, Primary mediastinal large B-cell lymphoma; ASCT, Autologous stem-cell transplantation; GCB, germinal center B; LDH, lactate dehydrogenase.